Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01906528 · ClinicalTrials.gov registry record · Phase 1
Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01906528 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 20 participants.
The verdict
NCT01906528, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Muscle relaxants are drugs providing muscle relaxation during surgical treatment. Previous studies have shown that males and females respond differently to this kind of drug. Our hypothesis is that males are more sensitive to the effect of Mivacurium (a muscle relaxant) than females, meaning that males need a lower blood concentration of the drug than females in order to obtain a given effect.
Interventions
- DRUG Mivacurium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01906528
The ClinicalTrials.gov registry entry for NCT01906528 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mivacurium is the first listed.
NCT01906528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01906528 about?
NCT01906528 is a clinical study titled "Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium". Muscle relaxants are drugs providing muscle relaxation during surgical treatment. Previous studies have shown that males and females respond differently to this kind of drug. Our hypothesis is that males are more sensitive to the effect of Mivacurium (a muscle relaxant) than females, meaning that ma...
What is the current status of trial NCT01906528?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-03. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01906528?
The interventions under investigation include: Mivacurium (DRUG).
Who is sponsoring clinical trial NCT01906528?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.